Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trilostane · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Trilostane | DRUG | Taken orally once a day for three days then twice daily thereafter. |
| Hydrocortisone | DRUG | Taken orally with trilostane. |
Inclusion Criteria: * Histologically confirmed prostate adenocarcinoma * Disease progression despite androgen depravation therapy and antiandrogen withdrawal * Progressive measurable disease or bone scan progression or PSA progression * Serum total testosterone \< 50ng/ml * Creatinine \< 2.0 mg/dl ...
Top 20 of 53 competitors
Trilostane is an investigational small molecule being studied for the treatment of prostate cancer, specifically androgen-independent prostate cancer and prostate adenocarcinoma. It is in Phase 2 clinical development for this indication. The drug is not approved and remains under investigation.
Trilostane is being developed by Sanofi, a company traded under the ticker symbol SNY. The drug is currently in Phase 2 clinical development for prostate cancer.
Trilostane is in Phase 2 clinical development for prostate cancer. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
Trilostane has one completed clinical trial, NCT00181597, titled "Trilostane for Androgen-Independent Prostate Cancer." This Phase 2 study enrolled 24 male participants aged 18 years and older in the United States and was not randomized, double-blind, or controlled.
Trilostane is not FDA approved for prostate cancer. It is an investigational drug currently in Phase 2 clinical development. A completed Phase 2 trial (NCT00181597) evaluated its use in androgen-independent prostate cancer, but approval status has not been established.